HIV-1 AccuVert Seroconversion Panel (PRB966) / Batch #
|
|
- Leona Bennett
- 6 years ago
- Views:
Transcription
1 s/co c/ml DATA SHEET OVERVIEW (PRB966) is a 10-member panel of undiluted, naturally occurring plasma samples. Panel members represent serial bleeds collected from a single patient over the course of 51 days during the development of an HIV infection and subsequent response. Each sample represents a single collection event. No preservatives were added. Test results from commercially-available, antigen, and antibody assays are included for characterization of each panel member. This panel of human plasma samples demonstrates a change in expression from negative to positive for HIV-1 analytes during the development and progression of an HIV infection. All results were generated using commercially available tests performed at SeraCare or recognized reference laboratories (RL) by individuals who routinely use these procedures. For Research Use Only. Not for use in diagnostic procedures. Data are provided for informational purposes. SeraCare Life Sciences does not claim that others can duplicate test results exactly. CAUTION: Potentially infectious materials. Follow Universal Precautions. Panel members were found positive for markers of HIV infection; all were found negative for HBsAg, HBV DNA, anti-hcv and HCV RNA. Evolution of HIV Markers in Early Infection HIV-1/2 & Group O Positive cut-off 3.00E E E E E E Days since first bleed 0.00E+00 This graph demonstrates the evolution of early HIV infection, illustrated with test results over time for different analytes or analyte combinations. Assays displayed are Standard, Beckman Coulter, ARCHITECT combo and the PRISM HIV-1/2 & group O. Page 1 of 5
2 Information SeraCare Batch # SeraCare Donor ID Bleed Date Days Since 1 st Bleed 01 BM BD Oct BM BD Oct BM BD Oct BM BD Oct BM BD Nov BM BD Nov BM BD Nov BM BD Nov BM BD Nov BM BD Nov Ultra Sensitive (copies/ml) 1 Standard (copies/ml) 1 01 <50 NT 02 <50 NT 03 <50 NT 04 <50 NT 05 <50 NT x 10 2 NT 07 NT 1.9 x NT 2.8 x NT 4.8 x NT 8.2 x 10 4 Test Date 16-Aug Aug-2007 Test Site SeraCare SeraCare Kit Part Code Kit Lot No. J00667 J00667 Kit Exp. Date Mar-2008 Mar Results in bold red are considered reactive. NT = not tested Page 2 of 5
3 HIV-1 Antigen & Confirmatory Beckman Coulter Perkin Elmer Zeptometrix Elecsys OraSure Rapid HIV-1 (Result) Maxim Western Blot HIV-1 2 Band Pattern Result NEG No Bands NEG NEG No Bands NEG NEG No Bands NEG NEG No Bands NEG NEG No Bands NEG NEG No Bands NEG NEG No Bands NEG NEG No Bands NEG NEG No Bands NEG NEG No Bands NEG Test Date 04-Apr Aug Aug May Aug Aug-2007 Test Site SeraCare SeraCare SeraCare RL SeraCare SeraCare Kit Part Code NEK 050A NA Kit Lot No. 2066F A Kit Exp. Date 18-Apr Mar Jan-2008 Aug Sep Oct Formerly Calypte - Cambridge Biotech Western Blot Page 3 of 5
4 /Ab ARCHITECT AxSym PRISM Dade Behring Enzygnost Integral II Elecsys Combination Murex Combination Test Date 10-May May May Jun May May-2007 Test Site RL RL RL RL RL RL Kit Part Code NA NA NA NA NA NA Kit Lot No HN LU HN L Kit Exp. Date 02-Jan Oct Oct Jun-2008 Nov Nov-2007 Page 4 of 5
5 HIV-1/2 Antibody & Group O 1 EIA HIV-1/2 PRISM HIV O Plus AxSym Siemens ADVIA Centaur enhanced Murex HIV 1.2.O > > Test Date 31-Jul May May May May-2007 Test Site SeraCare RL RL RL RL Kit Part Code 3A77 NA NA NA NA Kit Lot No M HN LU L Kit Exp. Date 27-Sep Jan Oct Mar Feb-2008 The package insert for this panel can be found at A printed copy of the package insert or data sheet may be requested by at info@seracare.com, or by phone at ASK ABOUT RELATED SERACARE PRODUCTS AccuSet Performance Panels HIV Disease State Materials ACCURUN Independent Quality Controls SeraCon and Basematrix Processed Plasma Page 5 of 5
HIV-1 Seroconversion Panel PRB964
A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers and clinical
More informationExpression of HIV-1 Markers During Progression of Infection E E E Days Since 1st Bleed
Seroconversion OVERVIEW HIV-1 AccuVert TM Seroconversion PRB970 is a 4 member, 1.0 ml per vial panel of undiluted, naturally-occurring plasma samples. members represent serial bleeds collected from a single
More informationAccuSet Anti-HIV-1 Mixed Titer Performance Panel
signal to cut-off (s/co) DATA SHEET OVERVIEW PRB205(M3) is a modified 16-member panel originating from Anti- HIV-1 Mixed Titer PRB205(M2). Panel members 3, 5, 6, 17, 21, 22, 23, 24, and 25 from the original
More informationAccuSet HCV Performance Panel
Signal to cutoff (s/co) DATA SHEET OVERVIEW AccuSet HCV (0810-0204) is a 25-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members
More informationAccuVert HIV-1 Seroconversion Panel PRB955 ( ) / Batch #
Signal to cutoff (s/co) Copies per ml (c/ml) OVERVIEW AccuVert is a 5-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent
More informationHIV-1 AccuVert TM Seroconversion Panel
PACKAGE INSERT PRB954 (0600-0238) INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot test methods. Characterized
More informationHIV-1 Seroconversion Panel PRB975
Seroconversion OVERVIEW is a five member HIV Seroconversion collected from a single donor over a 14 day period in 2002, prior to antibody seroconversion. -03 is a challenging sample for HIV RNA assays,
More informationAccuSet HIV-1/2 Performance Panel
OVERVIEW AccuSet HIV-1/2 (0800-0380) is a 13-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent bleeds from multiple
More informationAccuVert HIV-1 Seroconversion Panel PRB974 ( )
PACKAGE INSERT PRB974 (0600-0258) INTENDED USE PRB974 (0600-0258) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers
More informationAccuSet Anti-HIV-1 Mixed Titer Performance Panel
PACKAGE INSERT PRB205(M3) / (0800-0379) INTENDED USE The Performance Panel PRB205(M3) / (0800-0379) is intended for use by diagnostics manufacturers and clinical laboratorians to evaluate their HIV-1 test
More informationHIV-1 Seroconversion Panel
OVERVIEW This Data Sheet contains test results specific for HIV-1. s are undiluted aliquots from plasma units collected from a single donor. No preservatives were added. CAUTION: Potentially infectious
More informationHIV-1 Seroconversion Panel
A SERACARE PANEL PRODUCT Seroconversion INTENDED USE The Seroconversion is a group of serial bleeds from an individual plasma donor during seroconversion. This is intended for use by diagnostics manufacturers
More informationHIV-1 Seroconversion Panel PRB973
A SERACARE PANEL PRODUCT INTENDED USE The is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostics manufacturers and clinical laboratorians
More informationAccuSet HBV Worldwide Performance Panel
PACKAGE INSERT 0805-033 INTENDED USE The is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot HBV test methods. Characterized samples
More informationAccuVert HBV Seroconversion Panel PHM941(M) ( )
PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics
More informationAccuSet Autoimmune Performance Panel
PACKAGE INSERT 0840-0001 INTENDED USE The 0840-0001 is intended for use by diagnostic manufacturers, researchers, and clinical laboratories to develop, evaluate, or troubleshoot autoimmune related test
More informationParvovirus B19 Mixed Titer Performance Panel PVP201
A SERACARE PANEL PRODUCT INTENDED USE The is a panel of naturally occurring plasma specimens. This panel is intended for use by diagnostic manufacturers and clinical laboratories to evaluate their Parvovirus
More informationHIV Serology Quality Assessment Program Revised Summary for Panel HIVSER 2017Oct27
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Revised
More informationFINAL REPORT HBV Serology External Quality Assessment Scheme
FINAL REPORT HBV Serology External Quality Assessment Scheme Programme codes: HBVC4310, HBVC435 Panel ID: 2008/Mar/11 HBV Serology EQAS Panel ID 2008/Mar/11 Page 1 of 9 The NRL is a: NATA-accredited proficiency
More informationHIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More information100 Abbott Park Road Abbott Park, IL Trade Name: ARCHITECT HIV Ag/Ab Combo Assay Approved Date: 18-JUN-2010
Currently Approved CBER Device Premarket Applications (PMAs) As of Nov 10, 2014 Sorted by Applicant Name BP090080-0 BP060002-0 BP120037-0 BP090022-0 BP090032-0 BP040046-0 BP100064-0 BP140120-0 Abbott Laboratories
More informationEvolution of HIV Diagnostics. Goals for the 2010 Conference. Bernard M. Branson, M.D. CDC Division of HIV/AIDS Prevention
Evolution of HIV Diagnostics and Goals for the 2010 Conference Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics CDC Division of HIV/AIDS Prevention Evolution or other influences like
More informationHIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationHIV Serology Quality Assessment Program Summary for Panel HIVS Oct22
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationRoutine HIV Testing Community of Practice Session #2
Routine HIV Testing Community of Practice Session #2 Presenters: Denver Prevention Training Center Broward Community & Family Health Centers, Inc. 20 March 2016 Communities of Practice Routine HIV Testing
More informationInfectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance
Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa
More informationFINAL REPORT HBV Serology External Quality Assessment Scheme
FINAL REPORT HBV Serology External Quality Assessment Scheme Programme codes: HBVC4310, HBVC435 Panel ID: 2008/Oct/28 HBV Serology EQAS Panel ID 2008/Oct/28 Page 1 of 11 The NRL is a: NATA-accredited proficiency
More information2018 HIV and HCV Diagnostic Testing Survey
2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will
More informationSituation of XMRV and Blood Transfusion. Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011
Situation of XMRV and Blood Transfusion Celso Bianco, MD ISBT Working Party on TTID Lisbon, June 19, 2011 Lombardi et al. Science 326, 585 (2009) Conclusions: CFS and XMRV XMRV found in 67% of CFS patients
More informationOpportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests
Opportunities Created by Diagnostic HCV and HIV Nucleic Acid Tests Ann Winters, MD Medical Director, Viral Hepatitis Program, Bureau of Communicable Disease, New York City Department of Health and Mental
More informationFlu Watch. MMWR Week 3: January 14 to January 20, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 3: January 14 to January 2, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationto be notified: all parties involved in the graduated plan procedure. Annexes
Paul-Ehrlich-Institut Postfach 63207 Langen, Germany To all marketing authorisation holders of cellular blood preparations and therapeutic single plasmas as well as authorisation holders of stem cells
More informationFlu Watch. MMWR Week 4: January 21 to January 27, and Deaths. Virologic Surveillance. Influenza-Like Illness Surveillance
Flu Watch MMWR Week 4: January 21 to January 27, 218 All data are provisional and subject to change as more reports are received. Geographic Spread South Carolina reported widespread activity this week.
More informationHumaTex CRP. Design Verification. Contents
Design Verification HumaTex CRP Contents 1 Function... 2 2 Reproducibility... 2 3 Sensitivity and dynamic range... 2 Preparation of serum control panel... 2 Sensitivity test results... 2 Prozone check...
More informationHIV Testing Technology and the Latest Algorithm
HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with
More informationLearning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016
New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new
More informationCARIBBEAN REGION EXTERNAL QUALITY ASSESSMENT SCHEME. Evaluation Booklet. Performance Evaluation Panel OPS0106 C. Coordination:
EXTERNAL QUALITY ASSESSMENT SCHEME Evaluation Booklet CARIBBEAN REGION Performance Evaluation Panel OPS0106 C Coordination: Fundação Pró-Sangue Hemocentro de São Paulo Pan American Health Organization
More informationCurators of the University of Missouri - Combined January 1, 2016 through December 31, 2016
Cost Management Report Delta Dental Network Coverage Network Utilization Discount Delta Dental PPO Network 28.3% 29.4% Delta Dental Premier Network 67.0% 12.0% Total 95.3% Savings Categories $ % of Net
More informationARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What
More informationFAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)?
FAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)? A: We send letters and/or profiles to PCPs with female members
More informationMcLean ebasis plus TM
McLean ebasis plus TM Sample Hospital (0000) Report For Qtr HBIPS Core Measures McLean Hospital 115 Mill Street Belmont, MA 02478 1 2012 Department of Mental Health Services Evaluation Tel: 617-855-3797
More informationP0078 SeraQ ARCHITECT P0078
P0078 SeraQ ARCHITECT P0078 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3 Key
More informationConfirmatory Testing Algorithm. Routine Donor Testing Algorithm
Confirmatory Testing Algorithm Blood Confirmatory ABO/Rh Beckman Coulter PK-ABO/Rh Immucor NEO ABO/Rh Immucor NEO ABO/Rh Immucor Manual ABO/Rh Typing Immucor Manual ABO/Rh Typing Discrepancy Resolution
More informationWhat can we learn from EQAs and audits for cardiac marker testing?
What can we learn from EQAs and audits for cardiac marker testing? Dr P. O. Collinson MA MB BChir FRCPath MD FACB Consultant Chemical Pathologist and Director of Clinical Blood Sciences, Head of Vascular
More informationHIV SELF-TESTING AFRICA
UNITAID PSI HIV SELF-TESTING AFRICA Zambart: Interim Results of Clinical Performance Study Alwyn Mwinga Overview of Presentation Study Objectives Clinical Performance study Visual stability study Progress
More informationTEST REQUEST INFORMATION- VIROLOGY
Chlamydia/ Gonorrhea Nucleic Acid Amplification VC75 Qualitative Nucleic Acid Amplification SPECIMEN: Genital swab or first catch urine CONTAINER:GEN-PROBE APTIMA 2 Combo swab transport tube or urine transport
More informationDEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE
DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut
More informationHIV Testing. Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center
HIV Testing Susan Tusher, LMSW Program Coordinator The Kansas AIDS Education and Training Center The Number of Persons in the US Living with HIV Continues to Increase Over 1 Million people are estimated
More informationImpact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company
More informationCrisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019
Crisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019 20-Jan 21-Jan 22-Jan 23-Jan 24-Jan 25-Jan 26-Jan between January 14th - January 21st Please Note: The application deadline
More information18 Week 92% Open Pathway Recovery Plan and Backlog Clearance
18 Week 92% Open Pathway Recovery Plan and Backlog Clearance Page 1 of 6 17.05.2012 1.0 Background 18-Week 92% Open Pathway RECOVERY PLAN The Trust has achieved compliance against the admitted and non-admitted
More informationFor information only: all participants in the graduated plan procedure. 7 January 2013
Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: All marketing authorisation holders of cellular blood products and therapeutic single plasma as well as holders of an authorisation for stem cells
More informationUpdate on WHO Prequalification of IVDs
Update on WHO Prequalification of IVDs Geneva, 11 March 2016 Mercedes Perez Gonzalez Anita Sands Prequalification Team - Diagnostics World Health Organization Outline Progress and Pipeline Ongoing concerns
More informationTri-County Opioid Safety Coalition Data Brief December 2017 Clackamas, Multnomah, and Washington Counties
Medicaid-Funded Alternative Treatment for Back Pain in the Tri-County Region Key Findings The percentage of members with a back pain diagnosis who received an alternative treatment increased from 29% in
More informationOverview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station
Click here for the corrections made < Reference > December 3, 212 Tokyo Electric Power Company Overview of the Radiation Exposure Doses of the Workers at Fukushima Daiichi Nuclear Power Station * As of
More informationFrom Analytics to Action
From Analytics to Action Overview So, what are we talking about here? How to make incremental changes to your digital content that will result in positive user actions Overview Rooted in the hard sciences
More informationHTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2017Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2017Apr19
More informationArmed Services Blood Program
Armed Services Blood Program Defense Health Board Concerns Regarding the Collection and Transfusion of Non-FDA Compliant Blood Products in Theater Information Brief Defense Health Board 17 August 2009
More informationThe Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing
PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides
More informationQuit Rates of New York State Smokers
Quit Rates of New York State Smokers Sara M. Abrams, MPH Data Manager NYS Smokers Quitline Sara.Abrams@roswellpark.org September 6, 20 Presentation Outline Basic Quitline Service How Quit Rates are defined
More informationT pallidum. Table of contents
An assessment of Point of Care Tests for Hepatitis B, Hepatitis C, HIV and Syphilis for use in an Operational Environment to Provide Emergency Transfusion Support Microbiological Diagnostics Assessment
More informationCustomer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands
PRODUCT CATALOGUE Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 sales@bioqcontrol.com
More informationQuality Control Solutions
Quality Control Solutions 1 CONTENT QCONNECT 3 ABOUT DIAMEX 6 ABOUT NRL 7 ABOUT EXACT DIAGNOSTICS 7 PRODUCTS 8 SEROLOGY MULTIMARKER RANGE 10 SEROLOGY SINGLE ANALYTE RANGE 16 NAT CONTROL RANGE 19 EXACT
More informationCurators of the University of Missouri - Combined January 01, 2013 through December 31, 2013 Cost Management Report
Cost Management Report Program Design Specifics Standard Claims Management SAVINGS CATEGORIES SAVINGS RESULTS % OF NET SUBMITTED DOLLARS % OF PAID DOLLARS Deductible Applied $1,296,627 5.68% 9.78% Patient
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More informationP0180 SeraQ LIAISON P0180
0 P0180 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3 Key to Symbols Used...
More informationFGSZ Zrt. from 28 February 2019 till 29 February 2020 AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS
AUCTION CALENDAR: YEARLY YEARLY BUNDLED AT CROSS BORDER POINTS FIRM CAPACITY - First Monday of July 01.06.2019* 01.07.2019 07:00 01.10.2019 04:00 01.10.2020 04:00 2019/2020 01.10.2020 04:00 01.10.2021
More informationSeasonality of influenza activity in Hong Kong and its association with meteorological variations
Seasonality of influenza activity in Hong Kong and its association with meteorological variations Prof. Paul Chan Department of Microbiology The Chinese University of Hong Kong Mr. HY Mok Senior Scientific
More informationHTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLVSER 2016Oct28
More informationSleep Market Panel. Results for June 2015
Sleep Market Panel Results for June 2015 Notes: o This is a monthly trending report of panel member data along with additional analysis by: Sleep labs affiliated with Hospitals vs. Independent Labs o Hospital
More informationDraft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc)
Date: 6 January 2012 Draft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc) WHO Collaborating Centre for HIV/AIDS Diagnostic and Laboratory Support Department of Clinical Sciences
More informationPublished by the Pharmaceutical Services Division to provide information for British Columbia s health care providers
Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Keeping the Lines Clear... 1 Newsletter Notification Service... 1 Special
More informationAn Updated Approach to Colon Cancer Screening and Prevention
An Updated Approach to Colon Cancer Screening and Prevention Kevin Liebovich, MD Director for Quality for Gastrointestinal diseases Advocate Condell Medical Center Colon Cancer Screening and Prevention
More informationDonor Screening in The Region. Vincini GA NRL, Melbourne, Australia
Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management
More informationTHE PORTUGUESE COMMUNITY SCREENING NETWORK
THE PORTUGUESE COMMUNITY SCREENING NETWORK COBATEST Annual Network Meeting 14 May 2018 Presented by: Name goes here Paula Meireles, on behalf of the Community Screening Network EPIUnit ISPUP FUNDING (from
More informationSTRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.
STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. Acknowledgements This project was fully funded by Center For Disease Control
More informationSerology and International units
Serology and International units L. Grangeot-Keros, National Reference Laboratory for Rubella, Virology Department, A. Béclère Hospital, Clamart, France Detection of rubella-specific IgG antibody Assays
More informationMaximizing Cornea and Tissue Donation through Specimen Quality
Maximizing Cornea and Tissue Donation through Specimen Quality Robert W. Bresler, Sydney D. Gastreich, Elias G. Koulouriotis, Linda S. Martin, Susan Diane Brockmeier, Chak-Sum Ho, PhD Abstract Purpose:
More informationHIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)
HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC
More information1 st and 2 nd Generation EIA
HIV Diagnostic Tests Bernard M. Branson, M.D. Associate D irector for Laboratory D iagnostics Division of HIV/AIDS Prevention Centers for D isease Control & Prevention The views expressed in this presentation
More informationProgress Report March 2016
Progress Report March 2016 Table of Contents Background to project 3 Assays performed to date 3 Correctional Services 5 Peri-Mining 6 Rif Concordance 7 Training: Laboratory and Clinical 7 Challenges identified
More informationSUPPLIER/MANUFACTURER PERFORMANCE REPORT
80/30 MOO 8 PHAHOLYOTHIN RD., T.KUKHOT, A.LUMLOOKKAR, PATHUMTHANI 30, THAILAND TEL : (66-) 9958 9, 995330 FAX : (66-) SUPPLIER/MANUFACTURER PERFORMANCE REPORT 80/30 MOO 8 PHAHOLYOTHIN RD., T.KUKHOT, A.LUMLOOKKAR,
More informationURGENT: Important Safety Information
July 2018 URGENT: Important Safety Information Subject: Notice of New Special Handling Instructions due to Potential for Cracked Needle Hubs and Particulate in Multiple Carpuject Luer Lock Glass Products-Corrected
More informationUsing all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic
Using all the data: Immunoassay signal-to-cutoff values provide useful information that should be considered in HIV diagnostic algorithms KP Delaney, M Pentella, B Bennett, and K Landgraf for the CDC/APHL
More informationFDA Reentry Guidance
FDA Reentry Guidance T. cruzi - Chagas, Hepatitis C and HIV Wednesday 6/6/18 Doug Denyer O Dina Hurlburt, SBB(ASCP)CM Outline Impact to Clients Review of FDA Guidance Documents Reentry Request Process
More informationWHO Parvovirus B19 Genotype Panel
WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)
More informationVIDRL & WHO Measles IgM Proficiency Panel Final Report Prepared by Jennie Leydon, Michaela Riddell & Dr Mike Catton Director VIDRL
VIDRL & WHO Measles IgM Proficiency Panel 00702 Final Report Prepared by Jennie Leydon, Michaela Riddell & Dr Mike Catton Director VIDRL Table of Contents Tables and Figures... 3 Abbreviations... 4 Introduction...
More informationThe Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013
The Challenges in Developing and Commercializing HIV Tests that are Useful in Differentiating VISP/R VISP/R Workshop Bethesda, MD March 2013 Christopher Bentsen, M.S.,RAC, FRAPS Bio-Rad Laboratories, Redmond,
More informationImproving care of HIV-infected breastfeeding
Improving care of HIV-infected breastfeeding and their : Early results from the Partnership for HIV-free Survival Initiative in Uganda Tamara Nsubuga-Nyombi, URC IAS- Melbourne, Australia July 22nd, 2014
More informationDate : September Permit/License or Registration Application. Permit/License/ Notification/ Registration Description. Remark
Number 1. s 29 Jul 13 N/A Environmental Permit to construct the Passenger Clearance and associated works of the Hong Kong Zhuhai and Macao Bridge Boundary Crossing Facilities EP-353/2009/G 06 Aug 13 N/A
More informationDiagnostic Tests for HIV
Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,
More informationHepatitis C in Massachusetts Epidemiology and Public Health Response
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Hepatitis C in Massachusetts Epidemiology and Public Health Response Shauna Onofrey, MPH, Viral Hepatitis
More informationWHO Prequalification of Diagnostics Programme PUBLIC REPORT
WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: Murex HBsAg Version 3 with Murex HBsAg Confirmatory Version 3 Number: PQDx 0121-043-00 Abstract Murex HBsAg Version 3 with Murex HBsAg
More informationWithin 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma
Test Name *Minimum Collection Tubes Sample Stability ABO/Rh Blood Typing 50 µl cells EDTA whole blood (lavender-top) Within 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma
More informationAdvantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*
Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* HIV immunoassays grouped by generation, platform, and CLIA complexity + Advantages
More informationEQAS. Hemoglobin Program (BC80) Cycle 12: December 2014 December 2015 Sample No: 1 Sample Date: 17 Dec 14. Exceptions. Customer Information
(BC80) : December 2014 December 20 Exceptions None at this time. Legend: No Warnings Missing Result Late Results < < > * Amended Result (per participant s request) News Customer Information Please refer
More informationComplete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting
Complete Central Registry Treatment Information Requires Ongoing Reporting and Consolidation Well Beyond 6-Month Reporting Eric B. Durbin, DrPH, MS, Director of Cancer Informatics Frances E. Ross, CTR,
More informationSouth Plains Emergency Medical Services, Inc. P.O. Box Lubbock, Texas 79453
South Plains Emergency Medical Services, Inc. P.O. Box 53597 Lubbock, Texas 79453 June 28, 2017 TO: SPEMS EMS Services SUBJECT: SPEMS PARAMEDIC PROTOCOL VARIANCE With the ongoing medication shortages,
More informationAvian influenza in poultry, wild and captive birds (AI)
Avian influenza in poultry, wild and captive birds (AI) Analysis of ADNS data since 01/2018 Reporting period: 2018-01-01 2018-10-28 Data query: 2018-10-30 AGES DSR Austrian Agency for Health and Food Safety
More information